Dr Valentina Gburcik is an analyst at GlobalData covering cardiovascular and metabolic disorders.
Follow Valentina Gburcik: Website |
May 30, 2013 7:12 am by Valentina Gburcik | 1 Comments
Takeda announced positive late-stage results for its new type 2 diabetes drug, fasiglifam (TAK-875), the first GPR40 agonist to reach late-stage development. Fasiglifam has the potential to be a compelling…
Be the first to hear the latest industry news with our newsletters or by following us on Twitter & Facebook.